Ischemic Heart Disease (IHD) Drugs Market Set to Reach $7.86 Billion by 2029 with 4% Yearly Growth

What market dynamics are playing a key role in accelerating the growth of the ischemic heart disease (ihd) drugs market?
The Ischemic Heart Disease (IHD) drugs market is anticipated to experience significant growth due to the rising prevalence of diabetes and obesity. Diabetes, a chronic metabolic disease leading to heightened blood sugar levels, and obesity, characterized by an excessive build-up of body fat, are both conditions that detrimentally affect health and often contribute to ischemic heart disease. IHD drugs are commonly used in obese and diabetic individuals for the management of cardiovascular risk factors such as dyslipidemia and hypertension, thereby decreasing the threat of ischemic heart disease. As per the World Obesity Federation, a federation based in the UK steering global initiatives to avoid, treat, and lower obesity, by 2030, one billion people around the world, which includes 1 in 7 men and 1 in 5 women, will be suffering from obesity. The National Health Service, a UK government department, identified over half a million new individuals (549,000) at risk of developing type 2 diabetes in England in 2023, escalating the total count of pre-diabetic patients or those with non-diabetic hyperglycemia registered with a GP to 3,615,330. This marks a significant increase from the 3,065,825 recorded in 2022, representing a nearly 20% increase. Consequently, this rise in obesity and diabetes prevalence fuels the IHD drugs market's growth. Ischemic Heart Disease (IHD) Drugs Market Driver: The Upsurge In Heart Failure Incidences Fuels Growth In The Ischemic Heart Disease (IHD) Drugs Market

Get Your Ischemic Heart Disease (IHD) Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

How will the growth rate of the ischemic heart disease (ihd) drugs market shape industry trends by 2034?
The market size for drugs treating ischemic heart disease (IHD) has seen significant growth in the past few years. The market is projected to expand from $6.36 billion in 2024 to reach $6.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The substantial growth in the historical period can be attributed to numerous factors. These factors include the escalating global instances of ischemic heart disease, heightened awareness and improved diagnostics, alterations in lifestyle and food habits, governmental efforts towards cardiovascular health, collaborations in the domain of clinical trials, and insurance and reimbursement policies.

The market size for drugs treating ischemic heart disease (IHD) is poised for consistent expansion in the years ahead. The market is projected to reach $7.86 billion in 2029, representing a compound annual growth rate (CAGR) of 4.0%. The surge during the forecast period can be credited to factors such as an increasing elderly population, the rise of personalized medicine, focus on preventing cardiovascular diseases, global health strategies, and international research cooperation. Noteworthy trends within the prediction span comprise a gravitation towards precision medicine methods, prioritizing novel anti-atherogenic agents, progress in lipid-lowering treatments, the fusion of anti-inflammatory substances, along with the inception of antithrombotic and antiplatelet medications.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What trends are poised to drive the future success of the ischemic heart disease (ihd) drugs market?
Many leading enterprises within the ischemic heart disease (IHD) drug sector are centering their efforts on creating innovative myosin inhibitors, aiming to secure a stronger position within the market. A cardiac myosin inhibitor is a type of drug that curtails myosin functions in the cardiac muscle, effectively reducing contraction force. This proves especially helpful in situations like hypertrophic cardiomyopathy (HCM), a condition where excessive muscle thickening disrupts heart operation. For instance, Bristol Myers Squibb, an American pharmaceutical firm, introduced Camzyos (mavacamten) in April 2022. It's the pioneer cardiac myosin inhibitor sanctioned for treating adults displaying symptoms of the new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM) with the goal of enhancing their functional ability and easing symptoms. The medicine serves as a selective, allosteric, and reversible inhibitor for cardiac myosin, mitigating hypercontractility, left ventricular hypertrophy, and bettering cardiac filling pressures. This brings about a reduction in dynamic left ventricular outflow tract (LVOT) obstruction.

Which primary segments of the ischemic heart disease (ihd) drugs market are driving growth and industry transformations?
The ischemic heart disease (IHD) drugs market covered in this report is segmented -

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

Which geographical regions are pioneering growth in the ischemic heart disease (ihd) drugs market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the ischemic heart disease (ihd) drugs market landscape?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

What Is Covered In The Ischemic Heart Disease (IHD) Drugs Global Market Report?

•Market Size Forecast: Examine the ischemic heart disease (ihd) drugs market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the ischemic heart disease (ihd) drugs market for a structured understanding.
•Key Players Overview: Analyze major players in the ischemic heart disease (ihd) drugs market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the ischemic heart disease (ihd) drugs market.
•Segment Contributions: Evaluate how different segments drive overall growth in the ischemic heart disease (ihd) drugs market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the ischemic heart disease (ihd) drugs market.
•Industry Challenges: Identify potential risks and obstacles affecting the ischemic heart disease (ihd) drugs market.
•Competitive Landscape: Review strategic developments in the ischemic heart disease (ihd) drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.